TrialCardiovascular diabetology2023

Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.

Francesca Cinti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.